

Press release Feb. 28, 2013

YEAR-END REPORT JANUARY-DECEMBER 2012

Fourth quarter 2012

(compared with the same period 2011)

- Net sales increased by 88% to SEK 2,017k (1,071k).
- Operating loss before depreciation, amortization and impairment was SEK 4,335k (loss: 3,333k).
- Loss after financial items was SEK 8,465k (loss: 3,956k)*.
- Comprehensive income for the period was a loss of SEK 8,331k (loss: 3,835k)*.
- Comprehensive income per share basic and diluted totaled SEK -0.70 (-0.60).
- Cash flow from operating activities during the period was SEK -3,889k (-2,503k).
- Cash and cash equivalents at the end of the period totaled SEK 6,684k (7,563k).

Full-year 2012

(compared with full-year 2011)

- Net sales increased by 113% to SEK 6,080k (2,856k).
- Operating loss before depreciation, amortization and impairment was SEK -14,975k (- 12,435k).
- Loss after financial items was SEK 20,161k (loss: 13,758k)*.
- Comprehensive income was a loss of SEK 19,915k (loss: 13,608k)*.
- Comprehensive income per share basic and diluted totaled SEK -2.88 (2.37).
- Cash flow from operating activities during the period was SEK -14,848k (-12,150k).

*The impairment charges for the technology platform and patents have a negative impact of SEK 3,790k.

Selected financial data in brief (SEK thousands)	Oct. - Dec.		Jan.-Dec.	
	2012	2011	2012	2011
Net sales	2,017	1,071	6,080	2,856
Other operating income	447	435	1,014	741
Operating expenses	(11,090)	(5,462)	(27,276)	(17,343)
Comprehensive income for the period	(8,331)	(3,837)	(19,915)	(13,608)
Comprehensive income per share based on a weighted average of the number of outstanding shares	(0.70)	(0.55)	(2.04)	(2.37)
Cash flow from operating activities	(3,889)	(2,503)	(14,848)	(12,150)
Cash and cash equivalents	6,684	7,563	6,684	7,563

Events after the end of the period

Genovis' Board of Directors has decided that the nano portfolio, which focuses primarily on new contrast agents intended for both the preclinical and clinical markets, will be placed in the wholly owned subsidiary GeccoDots AB (formerly Eijdo research AB). Genovis will provide the subsidiary with about SEK 6 million in 2013. Operations will focus on product development of products for imaging of lymph nodes in malignant diseases, as well as for stem cell tracking.

With the authorization of the 2012 Annual General Meeting, the Board of Directors of Genovis has decided to conduct a rights issue to existing shareholders in which three (3) existing shares entitle the holder to subscription for one (1) new share at a subscription price of SEK 3.50/ share. As a result of this decision share capital could increase by a maximum of SEK 1,578,075.60 through the issuance of up to 3,945,189 shares. Following the completed rights issue, share capital will amount to a maximum of SEK 6,312,302.80 and the number of shares to 15,780,757. The company will raise about SEK 13.8 million before issue expenses, which are expected to be SEK 600,000. The issue will have a dilutive effect of 25% on the holdings of those who do not subscribe for their full stake.

Record date, March 28, 2013

Subscription period, April 4 – April 17, 2013

Principal owners Mikael Lönn and LMK Ventures AB have provided written subscription undertakings and will subscribe for their respective shares of the issue. In addition, Mikael Lönn and LMK Ventures AB have provided a guarantee along with subscription commitments guaranteeing 70% of the total issue volume. Guarantee fees of 5% will be charged on the amount exceeding the sum of the underwriters' subscription undertakings. The guarantee fee is SEK 256,141 to be divided equally among the underwriters.

CEO COMMENTS

During the fourth quarter, sales of products from our protein engineering portfolio increased by 88% compared with the same period in 2011--our strongest quarter ever. Looking at performance for the for twelve-month period of 2012 sales increased by 112%. FabRICATOR® continues to be our best-selling product, while our more processed products have increased the most in relative terms. The increase in sales is driven by a higher order value from established customers and a continued increase in the number of customers.

We also made some investments and hired more staff in 2012. Overall, our costs rose 38% during the year excluding impairments of patents and the technology related to the Nano portfolio of SEK 3,790k. We launched the campaign for a stronger team in sales and production in late 2011 and now I believe we have shaped an organization that will be able to take advantage of all of the opportunities that await in 2013.

We participated at two international conferences during the fourth quarter and worked with direct customer meetings. During the year as a whole we attended ten conferences, including seven at which we introduced new customers to the products from the protein engineering portfolio. We still have much work to do to reach out to our entire customer base. Our more experienced team enables us to take a more customer-focused approach and as a result our key customers are helping us to a greater extent in our marketing efforts by acting as ambassadors for the products.

Although we are prioritizing sales and delivery capacity for our existing products, during the fourth quarter we also worked intensively with the development of two new enzyme products. The first one, which we call FabULOUS, is an enzyme that supplements FabRICATOR and we are just starting to introduce it to our key customers in Europe and the United States. We will hold a broader launch later this spring, and later this year we are planning to add yet another new product.

In 2012, we worked with our nanostructures to strengthen the portfolio in terms of technology and patents, partly through collaborations with Lund University researchers. One of our most important tasks this year has been to meet potential customers, competitors and partners and in various ways we have analyzed the information, gained experience and identified needs for new technology and business models. As a result we will focus exclusively on new contrast agents that are based on our multimodal nanostructures. Although the preclinical market is a first step, the platform also has potential in the clinical market.

During the year we phased out operations in the subsidiary that consisted of providing medical imaging services. The restructuring of the operation in 2012 has resulted in an impairment of the holdings in the subsidiary since the business is no longer conducted in the way that was intended at the time of acquisition of Eijdo research AB in 2009, which affects the result of both the parent company and the Group.

We are already moving full speed ahead in 2013 and our two product portfolios will take the next step into each market. For the nano portfolio the main objective is to transition from testing and introduction of the technology into sales. Our unique enzymes have made progress and we now have our sights set on a positive cash flow for the protein portfolio at the end of the year.

Lund February


Sarah Fredriksson

CEO

SALES

During the fourth quarter, sales of products from our protein engineering portfolio increased by 88% compared with the same period in 2011, while the year-on-year increase is 113%. The table below shows sales per rolling twelve months

Sales, rolling 12 months (SEK thousand)



The sales trend can be explained in part by the new staff Genovis hired in 2012 to strengthen the production and sales team. Genovis now has a more efficient team that both concentrates on launches and product improvements and focuses on the customer. Active participation at major conferences and trade shows at which Genovis presented products and applications also resulted in new customers and increased sales.

The Life Science industry drives the market for these types of products in the quest to discover new biological drugs to treat a variety of diseases. Currently, more than 600 antibody-based drug candidates are in development and about 300 of them are in clinical trials. In diagnostics, antibody-based reagents are crucial because many biomarkers are detected using antibodies; antibodies also play a significant role as reagents in research.

Genovis' customers can primarily be found in biotech and pharmaceutical companies that develop monoclonal antibodies for medications. All major pharmaceutical companies are currently Genovis customers; they use the products to characterize drug candidates, develop production protocols and for quality control during production.

Genovis' sales are carried out both directly to end customers and in cooperation with distributors, who in turn market the products to companies on different regional markets. Distributors are currently represented in the US, Europe and Asia. The largest market for Genovis' products is the US, which accounts for about 60 percent of sales.

Revenue by geographic area, based on the country where the customer is located, SEK thousand	Jan.-Dec.	
	2012	2011
Nordic region	406	344
Europe	2,088	1,066
USA	3,566	1,715
Other countries	426	74
Total	6,080	2,856

GENOVIS PRODUCTS

Protein engineering portfolio

New products and product launches


During the fourth quarter, much of the development work concentrated on two new enzyme products. The first product, FabULOUS, is an enzyme that complements FabRICATOR®. This enzyme is now being introduced to Genovis' key customers. We will hold a broader launch later this spring. At the end of 2013 Genovis plans to add yet another new product.



Products

Genovis has developed several product concepts in which the active components are either FabRICATOR® or IgGZERO™. FabRICATOR is a unique enzyme that cleaves antibodies into two parts: a Fab fragment and an Fc fragment, with extremely high precision. IgGZERO is a protein that can specifically cleave sugar molecules that are found naturally on antibodies. Products can be ordered from a standard range or as custom-made products.

Customers use the products to screen new drug substances and for quality control in development and production of new antibody-based drugs. The products enable customers to carry out analyses faster with higher quality than competing technologies can offer, which means lower costs and greater efficiency for the customer. Genovis runs several development projects in the protein engineering portfolio, including both new product formats and completely new enzymes.



Using FabRICATOR to cleave the antibody into smaller parts provides customers with improved analysis results faster, saving both time and money for pharmaceutical companies.

Nano portfolio

Genovis has developed a technique to make nanostructures that act as contrast agents. Each nanostructure provides contrast for use in more than one imaging technique, such as MRI and ultrasound. Genovis' unique nanostructures are used as contrast agents to see and assess lymph nodes and tumors and to monitor stem cells using various medical imaging methods. The technology can be used in preclinical research to develop new drugs and to understand how tumors arise. The same technology can also be used in the clinical setting as an adjunct to surgery and diagnostics.

Genovis acquired its "upconverting technology" in 2011 and this technology is also integrated into the range of products the Company has chosen to focus on and highlight in 2013. In 2012 Genovis conducted reference studies and used the results to launch nanostructures for use as contrast agents. The studies focused on nanostructures based on upconverting technology, as well as nanostructures as contrast agents for use in ultrasonography and MRI. Developments during the year also resulted in unique applications and technology that are expected to strengthen the Company's intellectual property rights. The nano portfolio has been developed in cooperation with several groups at Lund University. The more commercial development, in which dialog with prospective customers and partners is a key component, was carried out in parallel during the year and the portfolio was first introduced at the 2012 World Molecular Imaging Congress.

Genovis has conducted two projects with full or partial external financing in 2012:

Sentinel Node project

Genovis is running this interdisciplinary project jointly with Lund University's Radiation Physics department. The final goal of the project is to produce a contrast agent that can be used both for diagnostics (using medical imaging) and as an aid during surgery.

** The project is financed by the Swedish Research Council and LMK Industri AB.*

LUPAS project

The project ended on December 31, 2012. Genovis' primary role was to provide knowledge about the design and production of nanostructures, as well as to work with communications and introductory business development of the project results. Over the course of the LUPAS project Genovis gained new knowledge about medical imaging of amyloid plaque in the preclinical setting and was particularly engaged in testing different nanoparticles as contrast agents for this purpose. The LUPAS project and the results it generated are presented on the LUPAS website, www.lupas-amyloid.eu.

RESULT AND FINANCIAL POSITION

The parent company conducted all of the Group's activities during 2012. To evaluate and test products from the nano portfolio, the parent uses equipment, including MRI, located at the premises of its subsidiary in Malmö. Net sales and operating profit/loss in the parent company are attributable to the primary and only business area: sales and/or outlicensing of research-based innovations. According to the Company, it does not meet the definition of geographical areas under IAS 14 and therefore no secondary segment information is provided.

The Group's financial performance

Net sales for the year increased to SEK 6,080k (2,856k), of which the fourth quarter increased to SEK 2,017k (1,071k). Other income during the six-month period increased to SEK 1,014k (741k); third-quarter other income rose to SEK 447k (435k).

Other operating income mainly consists of research support. The company's total expenses for the year totaled SEK -27,276k (-17,343k). Operating expenses are distributed among raw materials and consumables for SEK -2,425k (-1,168k), mainly due to changes in production procedures and royalty expenses as a result of increased sales. External expenses increased by SEK 2,985k to SEK -9,382k (-6,397) and mainly relate to increased marketing expenses.

Personnel costs increased by SEK 1,876k to SEK -10,223k (-8,347k). Furthermore, an impairment charge of SEK 915k was recorded for patents because Genovis no longer sells nanoparticles transfection reagents.

Operating loss for the year worsened to SEK 20,181k (loss: 13,745k). The corresponding results for the fourth quarter amount to a loss of SEK 8,491k (loss: 3,956k). Net financial items for the year totaled SEK -20k (-13k). Operating loss for the year worsened to SEK 19,915k (loss: 13,608), with a loss of SEK 8,331k (loss: 3,835k) reported for the fourth quarter. Since the Company phased out operations in the subsidiary that consisted of providing medical imaging services an impairment charge for the technology platform of SEK 2,875k was reported.

Consolidated investments and cash flow

The Group's net investment during the period totaled SEK 1,324k (870k) of which SEK 335k (226k) is attributable to property, plant and equipment, primarily laboratory and computers, and SEK 989k (644k) is attributable to investments in intangible assets.

At the end of the period cash flow was SEK -879k (3,489k). Cash flow from financing activities totaled SEK 15,293k (16,509k). During the period the Company carried out two rights issues.

Financial position

Cash and cash equivalents at the end of the period amounted to SEK 6,684k (7,563k). The liquidity of the Company is not considered to be sufficient to cover Genovis operations during the upcoming twelve-month period. The Board of Directors believes it is possible to raise the capital required in addition to the expected revenues through the approved rights issue in which the Company will raise about SEK 13.8 million before issue expenses. The issue is guaranteed up to 70%.

Interest bearing liabilities totaled SEK 0 (64k). During the period, loans were amortized for a total of SEK 245k.

Total shareholders' equity for the Group was SEK 13,633k after taking the net loss for the period into account.

Earnings per share, based on a weighted average of the number of outstanding shares, totaled SEK -2.88 (-2.37). The Group's equity ratio at the end of the period was 75% and equity per share was SEK 1.15 (3.13), based on fully diluted shares at year-end.

Taxes

The Group has a deferred tax asset that arises from the parent company, amounting to SEK 3,436k (3,128k) at the end of the period.

Employees

On December 31, 2012, the Group had fourteen employees, all in the parent company, compared with the same period the previous year, when the Group had ten employees, eight in the parent company and two in the subsidiary. An employee of the parent company holds an 80%-position as an industry-based doctoral student.

Share capital and Share Performance

Share capital at end of period amounted to SEK 4,734,227.2. The total number of shares was 11,835,568 with a par value of SEK 0.40.

Genovis shares are traded on NASDAQ OMX First North under the short name GENO. NASDAQ OMX First North is an alternative market, operated by the various exchanges within NASDAQ OMX. Companies on First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The Company's Certified Adviser is Thenberg & Kinde Fondkommission AB. Tel: +46 (0)31-745 50 00.

Major shareholders as of December 28, 2012

Name	No. of shares	Votes
Mikael Lönn	2,444,076	20.65%
LMK Ventures AB	1,450,000	12.25%
Hansa Medical AB	1,010,000	8.53%
Nordnet Pensionsförsäkring AB	668,972	5.65%
Försäkringsaktiebolaget, Avanza Pension	390,358	3.30%
Thorbjörn Fridh	225,550	1.91%
Åke Svensson	180,000	1.52%
JP Morgan Bank	109,429	0.92%
Didrik Hamilton	98,280	0.83%
René in 't Zandt	94,507	0.80%
other, 2,428 owners	5,164,396	43.64%
Total	11,835,568	100%

Parent company

Revenue for the period January-December was SEK 7,095k (3,407k), of which SEK 6,080k (2,666k) was attributable to sales and SEK 1,014k (741k) was attributable to research support for projects in the nanoparticle portfolio. Operating expenses for the period totaled SEK -23,215k (-14,649k), mainly attributable to payroll expenses, marketing and development projects as well as an impairment charge of SEK 915k for patents.

Operating loss for the period was SEK 16,120k (loss: 11,242k) and loss after net financial items was SEK 20,219 (14,300k).

Comprehensive income for the period was a loss of SEK 19,811k (loss: 14,300k).

The parent company income statement is charged with a conditional shareholder contribution to the subsidiary of SEK 610k (1,960k). Net capital expenditure totaled SEK 1,324k (1,870k). Liquidity at the end of the period was SEK 6,655k (7,034k).

The parent company has a deferred tax asset that amounted to SEK 3,436k (3,028k) at the end of the period, equivalent to a loss-carryforward of about SEK 15,6m, which is expected to be utilized in the foreseeable future. The Company's total tax loss amounts to SEK 103 million.

Subsidiary Eijdo research AB

(being renamed GeccoDots AB)

Eijdo research owns an MRI machine that is appropriate for clinical conditions and has access to all necessary infrastructure.

In 2012 Genovis used the subsidiary exclusively for internal product development together with the parent company's development group. The subsidiary has current assets amounting to SEK 256k, liabilities of SEK 154k and shareholders' equity of SEK 106k. The subsidiary did not have any income during the period and expenses totaled SEK 616k.

Related-party transactions

Mikael Lönn who owns a 20.65% stake in Genovis, underwrote the issue of 9,601,815 shares, corresponding with an amount of SEK 3,360,635, in the rights issue conducted in April- May 2012. Compensation for the underwriting was SEK 168k.

Outlook

Genovis is a research and development company and therefore corporate management has chosen not to issue any forecast. Although the Life Science field is relatively independent of business cycles, periods of uncertainty can influence our customers'

appetite to invest in new technology. With all development projects proceeding according to plan, we are positioned to make additional advances with respect to both new products and sales. The overarching goal for the year is to continue to focus on the commercial development of the Company's products the objective of a positive cash flow for the protein portfolio at the end of the year.

Risk factors

The Company's general view of the financial risks that could affect operations has not changed since the description published in the most recent annual report. Genovis' business risks include the difficulties in retaining skilled personnel and the risk that anticipated revenue might not materialize since competing companies have substantially larger financial resources at their disposal. For a detailed overview of the Company's financial risks please refer to page 60 in Genovis' 2011 annual report.

OTHER INFORMATION

Annual General Meeting

The Annual General Meeting will be held April 25, 2013 at Scheelevägen 22, Lund, Sweden.

Annual Report

The 2012 Annual Report is expected to be available on the Genovis website www.genovis.com and at the Genovis office as of April 4, 2013.

Proposal for dividend

The Board of Directors proposes that no dividend be paid for the 2012 financial year.

Nomination Committee

The Nomination Committee includes the following members: Mikael Lönn, Therese Karlsson representing LMK Ventures AB, Bo Håkansson, representing Hansa Medical AB and Torbjörn Fridh

Accounting policies

This year-end report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the relevant provisions of the Swedish Annual Accounts Act. The year-end report for the parent company has been prepared in accordance with chapter 9 of the Swedish Annual Accounts Act, Interim Reports. The accounting policies applied for the Group and the parent company are consistent with the accounting policies used in the preparation of the most recent annual report.

Consolidated statement of comprehensive income (SEK 000s)	Oct. - Dec.		Jan.-Dec.	
	2012	2011	2012	2011
Net sales	2,017	1,071	6,080	2,856
Other operating income	447	435	1,014	741
Raw materials and consumables	(650)	(825)	(2,425)	(1,168)
Other external expenses	(3,318)	(1,519)	(9,382)	(6,397)
Gross profit/loss	(1,504)	(838)	(4,713)	(3,968)
Personnel costs	(2,898)	(2,433)	(10,223)	(8,347)
Other operating expenses	67	(62)	(39)	(120)
Operating loss before depreciation, amortization and impairment	(4,335)	(3,333)	(14,975)	(12,435)
Depreciation of property, plant, and equipment and amortization of intangible assets	(4,156)	(623)	(5,206)	(1,310)
Operating loss	(8,491)	(3,956)	(20,181)	(13,745)
Net financial items	26	0	20	(13)
Loss after financial items	(8,465)	(3,956)	(20,161)	(13,758)
Taxes	134	119	246	150
Loss after tax	(8,331)	(3,835)	(19,915)	(13,608)
Attributable to shareholders in Genovis AB	(8,331)	(3,835)	(19,915)	(13,608)
Earnings per share (SEK)*				
- based on weighted average of the number of outstanding shares (basic and diluted).	(0.70)	(0.55)	(2.04)	(2.37)
Number of outstanding shares			9,778,112	5,752,244
Weighted average for the period	11,835,568	6,923,712	6,923,712	4,112,188
Number of shares at beginning of period	11,835,568	6,923,712	11,835,568	6,923,712
Number of shares at end of period	11,835,568	6,923,712	(2.04)	0.30
Share price at end of period, SEK	3,50	3,50	3,50	2,856

* Reverse split 1:10, with cut-off date April 10, 2012, has been taken into account in all periods covered by the interim report

Summary Consolidated Balance Sheet

Dec 31

(SEK thousands)

2012 2011

Assets		
<i>Non-current assets</i>		
Intangible assets	3,427	7,208
Property, plant and equipment	1,290	1,390
Financial assets	3,374	3,128
<i>Current assets</i>	3,383	2,152
Cash and cash equivalents	6,684	7,563
Total assets	18,158	21,441
Equity and liabilities		
Equity	13,633	18,010
Non-current liabilities	0	65
Current liabilities	4,525	3,366
Total equity and liabilities	18,158	21,441
Consolidated statement of changes in equity		
(SEK 000s)		
Amount at start of period	18,010	15,232
Rights issue	15,538	16,689
Reclassification of intangible assets	0	(303)
Net loss for the period	(19,915)	(13,608)
Amount at end of period	13,633	18,010
Attributable to shareholders in Genovis AB	13,633	18,010
Key financial ratios		
Equity/assets ratio	75%	84%
Equity per share at the end of the period - basic and diluted*	1.39	3.13

* Reverse split 1:10, with cut-off date April 10, 2012, has been taken into account in all periods covered by the interim report

Summary Consolidated cash and cash equivalents
 (SEK thousands)

	Oct. - Dec.		Jan.-Dec.	
	2012	2011	2012	2011
Cash flow from operations	(8,491)	(3,956)	(20,181)	(13,746)
Adjustment for items not affecting cash flow	4,156	622	5,206	1,310
Change in working capital	420	831	107	299
Net financial items	26	0	20	(13)
Cash flow from operating activities	(3,889)	(2,503)	(14,848)	(12,150)
Investing activities	(280)	(549)	(1,324)	(870)
Cash flow after investing activities	(4,169)	(3,052)	(16,172)	(13,020)
Financing activities	(64)	(420)	(245)	(180)
Rights issue	0	0	15,538	16,689
Cash flow for the period	(4,233)	(3,472)	(879)	3,489
Cash and cash equivalents at beginning of period	10,917	11,035	7,563	4,074
Cash and cash equivalents at end of period	6,684	7,563	6,684	7,563

Parent company

Summary Income Statement (SEK thousands)	Oct. - Dec.		Jan.-Dec.	
	2012	2011	2012	2011
Operating income	2,464	1,506	7,095	3,407
Operating expenses	(7,782)	(4,453)	(23,215)	(14,649)
Operating loss	(5,318)	(2,947)	(16,120)	(11,242)
Net financial items	(3,644)	(1,686)	(4,099)	(3,058)
Loss before taxes	(8,962)	(4,633)	(20,219)	(14,300)
Deferred tax on net loss for the period	408	0	408	0
Net loss for the period	(8,554)	(4,633)	(19,811)	(14,300)

Summary Balance Sheet (SEK thousands)	Dec 31	
	2012	2011
Assets		
Non-current assets	7,969	11,505
Current assets	3,316	2,109
Cash and cash equivalents	6,655	7,034
Total assets	17,940	20,648
Equity and liabilities		
Equity		
Restricted equity	16,752	39,713
Non-restricted equity	(3,343)	(22,030)
Liabilities		
Non-current liabilities	0	64
Current liabilities	4,531	2,901
Total equity and liabilities	17,940	20,648
Changes in equity		
(SEK 000s)		
Amount at start of period	17,683	15,294
Rights issue	15,537	16,689
Net loss for the period	(19,811)	(14,300)
Amount at end of period	13,409	17,683
Attributable to shareholders in Genovis AB	13,409	17,683

Parent company

 Summary Statement of cash flows
 (SEK thousands)

	Oct. - Dec.		Jan.-Dec.	
	2012	2011	2012	2011
Cash flow from operations	(5,319)	(2,947)	(16,121)	(11,242)
Adjustment for items not affecting cash flow	1,139	172	1,759	737
Change in working capital	541	830	443	257
Net financial items	26	0	21	(12)
Cash flow from operating activities	(3,613)	(1,945)	(13,898)	(10,260)
Investing activities	(576)	(1,150)	(1,774)	(2,830)
Cash flow after investing activities	(4,189)	(3,095)	(15,672)	(13,090)
Financing activities	(65)	(420)	15,293	16,509
Cash flow for the period	(4,254)	(3,515)	(379)	3,419
Cash and cash equivalents at beginning of period	10,909	10,549	7,034	3,615
Exchange rate difference in cash and cash equivalents	0	0	0	0
Cash and cash equivalents at end of period	6,655	7,034	6,655	7,034

Legal disclaimer

This report contains forward-looking information based on the current expectations of the management at Genovis. Although management believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove correct. Consequently, actual future results may vary materially from those implied in the forward-looking statements due to such changes in economic, market and competitive conditions, changes in the regulatory environment and other government actions, fluctuations in exchange rates and other factors.

This year-end report has not been reviewed by the Company's auditors.

Lund February 28, 2013

Genovis AB (publ.)

On behalf of the Board of Directors Sarah Fredriksson, CEO and President

For more information, please contact:

Sarah Fredriksson, CEO Tel: +46 (0)46-10 12 35

Susanne Ahlberg, IR tel +46 (0)40-10 12 38

Financial calendar 2013

Interim Report Jan.-March April 24

Half-Yearly Report, Jan.-June August 28

Interim Report Jan.-Sept. November 28

This interim report may be ordered from the Company or downloaded at the Genovis web site. Genovis AB, PO Box 790, SE-220 07 Lund, +46 (0)46-10 12 30, Fax: +46 (0)46-12 80 20